2023 World Conference on Lung Cancer (Posters)-P2.06. PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

P2.06. PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901) - PDF(Slides)

Back to course

Pdf Summary

The document is a final analysis of a phase 2 randomized controlled trial comparing the effectiveness and safety of sintilimab and pembrolizumab with or without chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The study achieved its primary goal, showing that sintilimab had a higher objective response rate (ORR) compared to pembrolizumab. The median progression-free survival (PFS) was similar for both drugs, while the median overall survival (OS) was not reached for sintilimab and was 17.5 months for pembrolizumab. <br /><br />Additional safety analysis showed that both drugs were generally well-tolerated, with few treatment discontinuations due to adverse events. The study design involved two stages, with a total of 34 patients evaluated in the final analysis. <br /><br />In conclusion, the study indicates that both sintilimab and pembrolizumab are effective and safe treatments for previously untreated advanced NSCLC. Sintilimab showed a higher ORR and potentially longer OS compared to pembrolizumab. The findings provide guidance on the use of PD-(L)1 inhibitors as first-line therapy for NSCLC. However, further research is needed, including a large phase 3 study, to further compare the efficacy of sintilimab and pembrolizumab. The document also includes acknowledgements to the patients, investigators, and funding sources involved in the trial, as well as details about the treatment arms, eligibility criteria, and randomization stratification used in the study.

Asset Subtitle

Si-Yang Liu

Meta Tag

Speaker Si-Yang Liu

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

phase 2

randomized controlled trial

sintilimab

pembrolizumab

chemotherapy

non-small cell lung cancer

objective response rate

progression-free survival

overall survival

PD-(L)1 inhibitors